Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Kearns, B. orcid.org/0000-0001-7730-668X, Pandor, A. orcid.org/0000-0003-2552-5260, Stevenson, M. orcid.org/0000-0002-3099-9877 et al. (5 more authors) (2016) Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. ISSN 1170-7690

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2016 Springer Verlag. This is an author produced version of a paper subsequently published in PharmacoEconomics. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Published: 22 October 2016
  • Published (online): 22 October 2016
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Funding Information:
FunderGrant number
NATIONAL INSTITUTE FOR HEALTH RESEARCH14/25/02
Depositing User: Symplectic Sheffield
Date Deposited: 05 Dec 2016 16:29
Last Modified: 12 Apr 2017 07:04
Published Version: http://doi.org/10.1007/s40273-016-0457-1
Status: Published
Publisher: Springer Verlag
Refereed: Yes
Identification Number: https://doi.org/10.1007/s40273-016-0457-1
Related URLs:

Download

Accepted Version


Embargoed until: 22 October 2017

Filename: KearnsB Caberzitaxel Paper.pdf

Request a copy

External copy

Share / Export

Statistics